These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 28331292)

  • 1. An open-label, two-period comparative study on pharmacokinetics and safety of a combined ethinylestradiol/gestodene transdermal contraceptive patch.
    Zhang C; Li H; Xiong X; Zhai S; Wei Y; Zhang S; Zhang Y; Xu L; Liu L
    Drug Des Devel Ther; 2017; 11():725-731. PubMed ID: 28331292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55-mg ethinyl estradiol/2.1-mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles.
    Westhoff CL; Reinecke I; Bangerter K; Merz M
    Contraception; 2014 Sep; 90(3):272-9. PubMed ID: 24969733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of bleeding patterns and cycle control using two transdermal contraceptive systems: a multicenter, open-label, randomized study.
    Gruber D; Skřivánek A; Serrani M; Lanius V; Merz M
    Contraception; 2015 Feb; 91(2):105-12. PubMed ID: 25453582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum.
    Kuhnz W; Baumann A; Staks T; Dibbelt L; Knuppen R; Jütting G
    Contraception; 1993 Oct; 48(4):303-22. PubMed ID: 8222659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding pattern and cycle control of a low-dose transdermal contraceptive patch compared with a combined oral contraceptive: a randomized study.
    Merz M; Kroll R; Lynen R; Bangerter K
    Contraception; 2015 Feb; 91(2):113-20. PubMed ID: 25453585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of different application sites on the bioavailability of a transdermal contraceptive patch containing ethinyl estradiol and gestodene: an open-label, randomized, crossover study.
    Höchel J; Schuett B; Ludwig M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Oct; 52(10):856-66. PubMed ID: 25138681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
    Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C
    Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study.
    Wiegratz I; Bassol S; Weisberg E; Mellinger U; Merz M
    Reprod Sci; 2014 Dec; 21(12):1518-25. PubMed ID: 24784719
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic drug-drug interaction between ethinyl estradiol and gestodene, administered as a transdermal fertility control patch, and two CYP3A4 inhibitors and a CYP3A4 substrate.
    Winkler J; Goldammer M; Ludwig M; Rohde B; Zurth C
    Eur J Drug Metab Pharmacokinet; 2015 Dec; 40(4):389-99. PubMed ID: 24997757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and adhesion of a transdermal patch containing ethinyl estradiol and gestodene under conditions of heat, humidity, and exercise: A single-center, open-label, randomized, crossover study.
    Zurth C; Schuett B; Casjens M; Ludwig M; Waellnitz K
    Clin Pharmacol Drug Dev; 2015 Jul; 4(4):245-55. PubMed ID: 27136904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study.
    Junge W; Heger-Mahn D; Trummer D; Merz M
    Drugs R D; 2013 Sep; 13(3):223-33. PubMed ID: 24043457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A two-centre, open-label, randomised study of ovulation inhibition with three transdermal contraceptive patches, each containing different amounts of ethinyl estradiol and gestodene in healthy, young women.
    Waellnitz K; Duijkers I; Klipping C; Rautenberg T; Rohde B; Zurth C
    J Obstet Gynaecol; 2016; 36(1):106-13. PubMed ID: 26421957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch.
    Stanczyk FZ; Archer DF; Rubin A; Foegh M
    Contraception; 2013 Jun; 87(6):744-9. PubMed ID: 23228503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. gestodene + ethinvlestradiol (APLEEK⁰). No place for a patch containing a third-generation progestin.
    Prescrire Int; 2016 Jan; 25(167):10. PubMed ID: 26942251
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of an ethinyl estradiol/gestodene transdermal contraceptive patch on the endometrium: a single-center, uncontrolled study.
    Merz M; Grunert J
    Womens Health (Lond); 2014 Jan; 10(1):37-43. PubMed ID: 24328597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive.
    van den Heuvel MW; van Bragt AJ; Alnabawy AK; Kaptein MC
    Contraception; 2005 Sep; 72(3):168-74. PubMed ID: 16102549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
    Archer DF; Stanczyk FZ; Rubin A; Foegh M
    Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A single-dose and 3-month clinical-pharmacokinetic study with a new combination oral contraceptive.
    Heuner A; Kuhnz W; Heger-Mahn D; Richert K; Hümpel M
    Adv Contracept; 1995 Sep; 11(3):207-25. PubMed ID: 8533624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence study of generic tablet formulations containing ethinylestradiol and chlormadinone acetate in healthy female volunteers.
    Bonn M; Eydeler U; Barkworth M; Rovati LC
    Arzneimittelforschung; 2009; 59(12):651-8. PubMed ID: 20108652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
    Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
    J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.